Menu

The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract pharmacy restrictions as part of an ongoing congressional probe of the drug pricing program.

Sen. Cassidy Mum on Next Steps for 340B Provider Probes

November 28, 2023 William Newton, Associate Editor/Senior Writer 340B Report Views

The influential senator who launched an inquiry into how two community health centers and two 340B hospitals use 340B savings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

William Newton

Senate Democrats Seek Drug Pricing Testimony from Three Pharma CEOs

340B’s Footprint in Medicare Part D Is Growing, Study Says